Constructive Interim Part I Outcomes of Zolmitriptan Transdermal Microporation System for the Therapy of Acute Migraine

SAN DIEGO, March 29, 2024. PassPort Applied sciences, Inc. (PPTI), based mostly in San Diego, a clinical-stage drug and medical machine growth firm, in the present day introduced optimistic interim outcomes from the Part 1 (Half A) scientific trial of Zolmitriptan PassPort using its proprietary transdermal microporation system for the remedy of acute migraine. Zolmitriptan is an FDA-approved prescription treatment used for treating migraine signs.

Zolmitriptan PassPort, a needle-free mixture system consisting of a microporation machine and zolmitriptan patch, was utilized on the person’s higher arm to ship zolmitriptan into the systemic circulation through micropores painlessly created within the pores and skin.

The open-label, randomized, crossover research consisting of 32 wholesome volunteers examined the tolerability and pharmacokinetics of Zolmitriptan PassPort with 3 totally different doses (0.75 mg, 1.5 mg, and three.0 mg) in comparison with oral administration of two.5 mg zolmitriptan.

Zolmitriptan PassPort was well-tolerated with no severe adversarial occasions. Zolmitriptan was detected within the plasma solely 2 minutes after Zolmitriptan PassPort administration, a lot sooner than quarter-hour seen for oral administration. The relative bioavailability of Zolmitriptan PassPort was roughly 160 to 200% in comparison with oral zolmitriptan.

“We’re happy with the tolerability and pharmacokinetics of Zolmitriptan PassPort in Part 1 Half A research. Our Zolmitriptan PassPort is predicted to reveal vital benefits of sooner onset of motion and better ache reduction for migraine sufferers with extreme nausea and sufferers who’re non-responsive to oral triptans. It can present a Finest-in-Class product possibility.” stated President and CEO Tomoyuki Fujisawa.

Half B research, at present underway, will consider the transdermal administration of a single dose at various websites, the topic’s stomach and higher thigh. The ultimate outcomes might be obtainable to the general public in Q3 2024.

PPTI holds unique international rights to develop and commercialize the Zolmitriptan PassPort however intends to out-license for additional scientific growth and commercialization.

About PassPort Applied sciences, Inc.

As a cutting-edge biotechnology entity, PPTI is dedicated to the swift growth and affected person supply of progressive prescribed drugs by the PassPort system. The corporate goals to continuously develop applied sciences that serve the pharmaceutical business and broader life sciences sectors. PPTI’s mission is to advance international well being outcomes.

The PassPort System integrates patented painless pores and skin microporation and dry patch formulation applied sciences to control drug supply by the micropores created within the pores and skin. This progressive system allows transdermal supply of not solely small molecules but additionally peptides, proteins, and RNAs for therapeutics and an infection vaccines.

Ahead-Wanting Assertion

Aside from historic data, all of the statements, expectations, and assumptions contained on this Press Launch are forward-looking statements. Precise outcomes could differ materially from these express or implicit within the forward-looking statements. Essential elements that would trigger precise outcomes to vary materially embrace: the early section of the scientific trial; dangers related to the drug growth course of; competitors; reliance on key personnel; and different dangers described in different PassPort Applied sciences, Inc. press releases and shows.

SOURCE PassPort Applied sciences, Inc.

Posted: March 2024

Associated articles

FDA Approves Intermezzo for Center-of-the-Evening Waking Adopted by Problem Returning to Sleep – November 23, 2011
Transcept Prescription drugs Pronounces Intermezzo PDUFA Motion Date of November 27, 2011 – October 7, 2011
Transcept Prescription drugs Pronounces Plan to Resubmit Intermezzo New Drug Utility Following Assembly with the U.S. Meals & Drug Administration – September 14, 2011
Transcept Prescription drugs Receives Full Response Letter from FDA on Intermezzo New Drug Utility – July 15, 2011
Transcept Prescription drugs Expects Full Response Letter on Intermezzo New Drug Utility Based mostly on Teleconference with FDA – July 13, 2011
Transcept Prescription drugs Resubmits Intermezzo New Drug Utility for the Therapy of Center of the Evening Awakenings – January 19, 2011
Transcept Prescription drugs Updates Plan for Intermezzo NDA Resubmission Following Teleconference With the FDA – March 25, 2010
Transcept Prescription drugs Offers Replace on Intermezzo Regulatory Evaluate – February 23, 2010
Transcept Prescription drugs Scheduled to Meet With FDA to Focus on Intermezzo Full Response Letter – November 24, 2009
Transcept Prescription drugs Receives Full Response Letter from FDA on Intermezzo New Drug Utility – October 30, 2009
Transcept Prescription drugs Pronounces Anticipated FDA Extension of Regulatory Evaluate Interval for Intermezzo – June 11, 2009
Transcept Prescription drugs Pronounces FDA Acceptance for Evaluate of New Drug Utility for Intermezzo – December 16, 2008
Transcept Prescription drugs Submits New Drug Utility for Intermezzo for Therapy of Center-of-the-Evening Awakenings – October 1, 2008